Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 93

    1.

    DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.

    Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, Unger C, Blum H, Hennig J, Milenkova TP, Tessier J, Krebs AD, Ryan AJ, Fischer R.

    J Angiogenes Res. 2009 Sep 21;1:5.

    PMID:
    19946413
    [PubMed]
    Free PMC Article
    2.

    Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

    Fasol U, Frost A, Büchert M, Arends J, Fiedler U, Scharr D, Scheuenpflug J, Mross K.

    Ann Oncol. 2011 Jun 21. [Epub ahead of print]

    PMID:
    21693769
    [PubMed - as supplied by publisher]
    3.

    Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

    Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.

    Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.

    PMID:
    16172907
    [PubMed - indexed for MEDLINE]
    4.

    Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

    Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM.

    J Clin Oncol. 2008 Oct 1;26(28):4572-8.

    PMID:
    18824708
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

    Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL.

    J Hepatol. 2012 Jan 12. [Epub ahead of print]

    PMID:
    22245891
    [PubMed - as supplied by publisher]
    6.

    A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

    Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M.

    J Thorac Oncol. 2008 Apr;3(4):386-93.

    PMID:
    18379357
    [PubMed - indexed for MEDLINE]
    7.

    Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy.

    Ansiaux R, Dewever J, Grégoire V, Feron O, Jordan BF, Gallez B.

    Radiat Res. 2009 Nov;172(5):584-91.

    PMID:
    19883226
    [PubMed - indexed for MEDLINE]
    8.

    PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

    Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J.

    NMR Biomed. 2005 Aug;18(5):308-21.

    PMID:
    15918178
    [PubMed - indexed for MEDLINE]
    9.

    Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

    Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP.

    J Clin Oncol. 2003 Nov 1;21(21):3955-64. Epub 2003 Sep 29.

    PMID:
    14517187
    [PubMed - indexed for MEDLINE]
    10.

    Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.

    Vriens D, van Laarhoven HW, van Asten JJ, Krabbe PF, Visser EP, Heerschap A, Punt CJ, de Geus-Oei LF, Oyen WJ.

    J Nucl Med. 2009 Nov;50(11):1777-84. Epub 2009 Oct 16.

    PMID:
    19837750
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

    Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M.

    J Clin Oncol. 2009 May 20;27(15):2523-9. Epub 2009 Mar 30.

    PMID:
    19332730
    [PubMed - indexed for MEDLINE]
    12.

    Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.

    van Laarhoven HW, Klomp DW, Rijpkema M, Kamm YL, Wagener DJ, Barentsz JO, Punt CJ, Heerschap A.

    NMR Biomed. 2007 Apr;20(2):128-40.

    PMID:
    17006886
    [PubMed - indexed for MEDLINE]
    13.

    Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.

    Saunders MP, Wilson R, Peeters M, Smith R, Godwood A, Oliver S, Van Cutsem E.

    Cancer Chemother Pharmacol. 2009 Sep;64(4):665-72. Epub 2009 Jan 29.

    PMID:
    19184020
    [PubMed - indexed for MEDLINE]
    14.

    Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

    Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS.

    J Clin Oncol. 2005 Aug 20;23(24):5464-73. Epub 2005 Jul 18.

    PMID:
    16027440
    [PubMed - indexed for MEDLINE]
    15.

    Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.

    Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N.

    Invest New Drugs. 2009 Jun;27(3):253-61. Epub 2008 Nov 11.

    PMID:
    19002384
    [PubMed - indexed for MEDLINE]
    16.

    Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.

    Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM.

    AJR Am J Roentgenol. 2010 Feb;194(2):W134-40.

    PMID:
    20093564
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.

    Ceelen W, Smeets P, Backes W, Van Damme N, Boterberg T, Demetter P, Bouckenooghe I, De Visschere M, Peeters M, Pattyn P.

    Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1188-96. Epub 2006 Feb 2.

    PMID:
    16457965
    [PubMed - indexed for MEDLINE]
    18.

    Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

    Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F.

    Oncologist. 2009 Apr;14(4):378-90. Epub 2009 Apr 6. Review.

    PMID:
    19349511
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Mitoxantrone: a review of its use in multiple sclerosis.

    Scott LJ, Figgitt DP.

    CNS Drugs. 2004;18(6):379-96. Review.

    PMID:
    15089110
    [PubMed - indexed for MEDLINE]
    20.

    Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial.

    Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.

    J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24.

    PMID:
    22025146
    [PubMed - in process]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk